PDSB (STOCKS)
PDS Biotechnology Corporation Common Stock
$0.670000
-0.041100 (-5.78%)
Prev close: $0.711100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Frank K. Bedu-Addo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $37.27M
- Employees
- 24
- P/E (TTM)
- -0.83
- P/B (TTM)
- 3.59
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.19 | $-0.22 | +0.0276 | +12.68% |
|
Jun 2025 (Q2)
|
$-0.21 | $-0.24 | +0.0280 | +11.76% |
|
Mar 2025 (Q1)
|
$-0.21 | $-0.25 | +0.0416 | +16.53% |
|
Dec 2024 (Q4)
|
$-0.21 | $-0.28 | +0.0722 | +25.58% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $32.23M |
| Research and Development | $19.15M |
| Other Operating Expenses | $13.08M |
| Operating Income/Loss | -$32.23M |
| Income/Loss From Continuing Operations After Tax | -$34.88M |
| Income/Loss From Continuing Operations Before Tax | -$36.05M |
| Income Tax Expense/Benefit | -$1.17M |
| Net Income/Loss | -$34.88M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$34.88M |
| Net Income/Loss Available To Common Stockholders, Basic | -$34.88M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.81 |
| Diluted Earnings Per Share | -$0.81 |
| Basic Average Shares | 44,993,315 |
| Diluted Average Shares | 44,993,315 |
| Assets | $34.71M |
| Current Assets | $27.89M |
| Noncurrent Assets | $6.81M |
| Fixed Assets | $125.64K |
| Other Non-current Assets | $6.69M |
| Liabilities | $25.25M |
| Current Liabilities | $13.33M |
| Accounts Payable | $5.18M |
| Other Current Liabilities | $8.15M |
| Noncurrent Liabilities | $11.92M |
| Equity | $9.45M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $9.45M |
| Liabilities And Equity | $34.71M |
| Net Cash Flow From Operating Activities | -$32.28M |
| Net Cash Flow From Operating Activities, Continuing | -$32.28M |
| Net Cash Flow From Investing Activities | $15.49M |
| Net Cash Flow From Investing Activities, Continuing | $15.49M |
| Net Cash Flow From Financing Activities | $8.73M |
| Net Cash Flow From Financing Activities, Continuing | $8.73M |
| Net Cash Flow | -$8.06M |
| Net Cash Flow, Continuing | -$8.06M |
| Comprehensive Income/Loss | -$34.88M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$34.88M |
| Other Comprehensive Income/Loss | -$26.93M |